IVIG in bone marrow transplantation

The principal causes of allogeneic transplant-related mortality are graft- versus-host disease (GVHD), interstitial pneumonia, and cytomegalovirus (CMV) infection. In bone marrow-transplant recipients, intravenous immunoglobulin (IVIG) has shown the ability to reduce the incidence of symptomatic CMV infection and interstitial pneumonia. Reductions in acute GVHD, bacteremia, septicemia, and local infection have been observed in IVIG recipients in the first 100 days post-transplant. Reduction in transplant-related mortality has also been observed, especially among adult patients receiving allogeneic marrow grafts.

Duke Scholars

Author Keith Michael Sullivan Medicine, Hematologic Malignancies and Cellular Therapy